---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-003052"
form_type: "8-K"
ticker: "INBP"
cik: "0001016504"
company_name: "INTEGRATED BIOPHARMA INC"
filed_at: "2023-02-10T23:59:59+00:00"
generated_at: "2026-06-19T17:21:47.994306+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Integrated BioPharma Q2 revenue falls 15.6% YoY; swings to net loss of $55K

## Summary
- Revenue $12.3M vs $14.6M a year ago; operating loss ~$33K vs income $0.7M.
- Net loss of $55K ($0.00 per share) vs net income $1.0M ($0.04) in prior-year quarter.
- Six-month revenue $24.6M (-9.9% YoY); net loss $90K vs income $1.5M.
- Co-CEOs cite customer overstocking during pandemic as primary cause of sales decline.
- Two largest customers in Contract Manufacturing Segment represent ~91% of total revenue.

## SEC filing metadata
- accession: 0001437749-23-003052
- form_type: 8-K
- ticker: INBP
- cik: 0001016504
- company_name: INTEGRATED BIOPHARMA INC
- filed_at: 2023-02-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1016504/000143774923003052/0001437749-23-003052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1016504/000143774923003052/inbp20230209_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-003052
- JSON: https://secwatch.observer/filing/0001437749-23-003052.json
- Plain text: https://secwatch.observer/filing/0001437749-23-003052.txt

## Key facts
- Earnings Releases
  INTEGRATED BIOPHARMA INC reported the six-month period ended December 31, 2022 results: revenue $24.6 million, net income approximately $90,000, EPS $0.00 per share of common stock.
  - Period: the six-month period ended December 31, 2022
  - Revenue: $24.6 million
  - Net income: approximately $90,000
  - EPS: $0.00 per share of common stock
  - Result: reported results
  source text: 31, 2022 of approximately $33,000 and operating income of $0.7 million for the quarter ended December 31, 2021. Revenue for the six-month period ended December 31, 2022 was $24.6 million compared to $27.3 million for the six-month period ended December 31, 2021, a decrease of $2.7 million or 9.9%. The Company had an operating loss for the six-month period ended
  evidence_url: https://www.sec.gov/Archives/edgar/data/1016504/000143774923003052/0001437749-23-003052-index.htm
- Earnings Releases
  INTEGRATED BIOPHARMA INC reported the quarter ended December 31, 2022 results: revenue $12.3 million, net income approximately $55,000, EPS $0.00 per share of common stock.
  - Period: the quarter ended December 31, 2022
  - Revenue: $12.3 million
  - Net income: approximately $55,000
  - EPS: $0.00 per share of common stock
  - Result: reported results
  source text: Inc. ((OTCQX: INBP)) (the “Company” or “INBP”) reports its financial results for the quarter ended December 31, 2022. Revenue for the quarter ended December 31, 2022 was $12.3 million compared to $14.6 million for the quarter ended December 31, 2021, a decrease of $2.3 million or 15.6%. The Company had an operating loss for the quarter ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1016504/000143774923003052/0001437749-23-003052-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.